Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts

Advanced ovarian cancer is very responsive to first line platinum therapy, however almost invariably it relapses with a resistant disease. We have reported that patient derived ovarian xenografts (PDXs), independently from the degree of the initial response to cisplatin (DDP), show a significantly l...

Descripción completa

Detalles Bibliográficos
Autores principales: Ricci, Francesca, Guffanti, Federica, Damia, Giovanna, Broggini, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450309/
https://www.ncbi.nlm.nih.gov/pubmed/28558767
http://dx.doi.org/10.1186/s12943-017-0662-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450309/
https://www.ncbi.nlm.nih.gov/pubmed/28558767
http://dx.doi.org/10.1186/s12943-017-0662-3

Ejemplares similares